

Amplify Weight Loss Drug & Treatment ETF

As of 6/30/24

FUND FACTS

| | |
|--------------------|------------|
| Ticker | THNR |
| CUSIP | 032108532 |
| Inception Date | 05/21/2024 |
| Primary Exchange | NYSE ARCA |
| Number of Holdings | 27 |
| Expense Ratio | 0.59% |

INDEX

| | |
|--------------|---|
| Index Name | VettaFi Weight Loss Drug & Treatment Index |
| Index Ticker | THNR |
| Weighting | Float-Adjusted Market Cap |
| Rebalance | Quarterly |
| Website | vettafi.com |

MARKET CAPITALIZATION

| | |
|------------------------|--------|
| Large Cap (> \$10B) | 92.65% |
| Mid Cap (\$2B - \$10B) | 6.98% |
| Small Cap (< \$2B) | 0.37% |

INVEST IN THE WEIGHT LOSS DRUG BREAKTHROUGH

THNR provides access to global companies involved in the pharmaceutical manufacturing of GLP-1 agonist or enablers of such businesses. THNR seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index.

REASONS TO INVEST

- 1 Significant Growth Opportunity:** The GLP-1 drug market is anticipated to grow from \$6 billion to \$130 billion by 2030.¹
- 2 Increasing Demand:** Pharmaceutical companies are accelerating production to meet demand as over 42% of U.S. adults and 1 billion people worldwide are obese.²
- 3 Diversified Access:** A global equity portfolio of companies pioneering GLP-1 therapies and the broader supply chain to capitalize on demand.

Beyond the Scale:

Recent studies have shown that GLP-1 drugs (glucagon-like peptide-1 agonists) have led to a 10-20% reduction in body-weight and lowered the risk of heart attack, stroke and cardiovascular death by approximately 20%.³

TOP 10 HOLDINGS

| TICKER | COMPANY | % WT. | TICKER | COMPANY | % WT. |
|---------|--------------|--------|---------|--------------------------|-------|
| LLY | Eli Lilly | 15.12% | WST | West Pharmaceutical | 4.87% |
| NVO | Novo Nordisk | 14.24% | TMO | Thermo Fisher Scientific | 4.80% |
| AZN | AstraZeneca | 7.12% | 4519 JP | Chugai Pharmaceutical | 4.67% |
| AMGN | Amgen | 5.20% | PFE | Pfizer | 4.65% |
| 4901 JP | FUJIFILM | 4.95% | ROG SW | Roche Holding | 4.61% |


Holdings and allocations are subject to change at any time and should not be considered a recommendation to buy or sell a security.

PERFORMANCE

| | CUMULATIVE (%) | | | ANNUALIZED (%) | | | |
|--|----------------|-----|-----------------|----------------|-------|-------|-----------------|
| | 1 MO. | YTD | SINCE INCEPTION | 1 YR. | 3 YR. | 5 YR. | SINCE INCEPTION |
| Fund NAV | 2.89% | N/A | 3.12% | N/A | N/A | N/A | N/A |
| Closing Price | 2.91% | N/A | 3.41% | N/A | N/A | N/A | N/A |
| VettaFi Weight Loss Drug & Treatment Index | 3.02% | N/A | 3.14% | N/A | N/A | N/A | N/A |

Fund inception date: 5/21/2024. The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. For performance data current to the most recent month-end please visit AmplifyETFs.com/THNR. Brokerage commissions will reduce returns. A fund's NAV is the sum of all its assets less any liabilities, divided by the number of shares outstanding. The closing price or market price is the most recent price at which the fund was traded. Indexes are unmanaged and it's not possible to invest directly in an index. The VettaFi Weight Loss Drug & Treatment Index is a float-adjusted market cap weighted index comprised of global companies who are manufacturers or enablers of the GLP-1 pharmaceutical business.

COUNTRY ALLOCATION




- United States (47%)
- Denmark (18%)
- Japan (13%)
- United Kingdom (7%)
- Switzerland (6%)
- Germany (5%)
- Hong Kong (3%)
- South Korea (1%)

INDUSTRY ALLOCATION



- Biopharma (80%)
- Healthcare Equipment & Services (12%)
- Technology Hardware & Equipment (5%)
- Chemicals (3%)

THEMATIC ALLOCATION



- Drug Manufacturers (70%)
- Enablers (30%)

SELECTION METHODOLOGY

The Index seeks to provide exposure to global companies pioneering GLP-1 drugs manufacturing or providing support and distribution services.

Eligible Universe

To be eligible companies must have a market cap of \$500M+ & classify as:

A Drug Manufacturers - available GLP-1 agonist drugs or are in clinical trials.

– OR –

B Enablers - engaged in outsourced development & manufacturing of GLP-1 drugs or support for production & distribution.

Weighting

- 70% Drug Manufacturers
- 30% Enablers

Each segment is float-adjusted market cap weighted.

Rebalancing

Quarterly rebalance in March, June, September & December.

Carefully consider the Fund's investment objectives, risks, charges, and expenses before investing. This and other information can be found in the Fund's statutory and summary prospectuses, which may be obtained at [AmplifyETFs.com](https://amplifyetfs.com). Read the prospectus carefully before investing.

Investing involves risk, including the possible loss of principal. There can be no assurance that the Fund's investment objectives will be achieved. The fund is new with limited operating history. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. The Fund invests in securities included in its Index regardless of their investment merit and may experience tracking error:

the differences in timing of trades, valuation, plus fees and expenses between fund and index.

A non-diversified fund and can invest a greater portion of its assets in securities of individual issuers which could cause greater fluctuations than a diversified fund. A narrowly focused portfolio concentrated in the pharmaceutical industry or healthcare sector, may exhibit higher volatility and be vulnerable to factors affecting them due to regulation, litigation, costs and competition.

Small and/or mid-capitalization companies may be more vulnerable to adverse general market or economic developments. Investments in foreign securities, especially in emerging markets, involve greater volatility and political, economic, and currency risks and differences in accounting methods beyond those of securities of U.S. issuers.

Amplify Investments LLC serves as the investment adviser to the Fund. Penserra Capital Management LLC serves as the investment sub-adviser to the Fund. Amplify ETFs are distributed by Foreside Fund Services, LLC.

¹Goldman Sachs, Anti-Obesity Drug Market. 10/2023. | Seeking Alpha, Goldman Sachs raises obesity drug market estimate to \$130B. 5/30/2024. ²World Health Organization, One in Eight People Are Now Living with Obesity, 03/2024. Pew Research Center, As Obesity Rates Rise in the US and Worldwide, New Weight Loss Drugs Surge in Popularity, 03/2024. ³Morgan Stanley, GLP-1: The Weight of Speculation, 12/2023. Medscape, Semaglutide Cuts Cardiovascular Events in Landmark Trial, 08/2023.

Not FDIC Insured | No Bank Guarantee | May Lose Value